Foamix Fortifies Its Patent Position in Mexico

Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, announced today that the Company has obtained another granted patent in Mexico.

Rehovot, Israel, June 05, 2012 --(PR.com)-- As of today Foamix has four granted patents in Mexico: MX Patent No.277933 entitled, “Foam Incorporating Eutectic Mixture”;

MX Patent No.268451 entitled, “Cosmetic And Pharmaceutical Foam”; MX Patent No.282498 entitled, “Oleaginous Pharmaceutical And Cosmetic Foam”; and MX Patent No.287254 entitled, “Saccharide Foamable Compositions."

Additionally, a notice of allowance has been received for another of Foamix's MX Patent applications.

These patents relate to several different platform foam technologies developed by Foamix and describe unique foam formulations and their uses in topical therapy.

"Mexico is an important country and these new achievements fortify Foamix’s patent position and offer greater protection for existing and potential partners of the company," remarks Dr. Dov Tamarkin, CEO of Foamix. "We are pleased that Mexico’s Patent Office and other Patent Offices around the world continue to recognize Foamix's innovation in the field of topical foams."
Contact
Foamix Ltd
Dorit Hayon
97289316233
www.foamix.co.il
Dov Tamarkin, CEO, Foamix Ltd, +972-8-9316233 or dov@foamix.co.il.
ContactContact
Categories